Bullish indicating open at $55-$60, IPO prices at $37
Investing.com - Truist Securities raised its price target on ANI Pharmaceuticals (NASDAQ:ANIP) to $77.00 from $65.00 on Monday, while maintaining a Hold rating on the stock. The company’s shares have surged 24.53% in the past week, reaching $83.93 and trading near their 52-week high of $83.80. According to InvestingPro data, five analysts have recently revised their earnings estimates upward.
The price target increase follows ANI Pharmaceuticals’ second-quarter results, which showed stronger-than-anticipated performance from its Cortrophin product line. This outperformance prompted management to raise guidance for the Cortrophin product.
Despite the positive developments with Cortrophin, Truist Securities noted that Iluvien continues to face market access challenges, while the company’s generics business performed in line with expectations.
The research firm acknowledged Cortrophin’s strength as the primary driver for the price target increase but expressed concerns about the company’s valuation at approximately 10 times EBITDA.
Truist Securities remains sidelined on ANI Pharmaceuticals, citing the company’s relatively high valuation compared to peers and its significant reliance on a single product to drive performance.
In other recent news, ANI Pharmaceuticals reported robust financial results for the second quarter of 2025, exceeding market expectations. The company’s adjusted earnings per share (EPS) reached $1.80, surpassing FactSet consensus estimates of $1.41. Revenue also outperformed forecasts, totaling $211.4 million compared to the anticipated $187.34 million. Cortrophin Gel revenue was a significant contributor, with $81.6 million in Q2, marking a 66% year-over-year increase and a 54% sequential rise from Q1 2025. Following these impressive results, ANI Pharmaceuticals raised its guidance for revenue, adjusted EBITDA, and EPS. In response to the strong performance, H.C. Wainwright increased its price target for ANI Pharmaceuticals from $84 to $93, maintaining a Buy rating. These developments highlight the company’s positive momentum and growth trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.